New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
11:10 EDTLINTA, ICPT, ACO, FENG, ODP, ARO, NDLS, GPI, KATEHigh option volume stocks
High option volume stocks: ACM KATE ARO TKMR ODP ICPT GPI FENG LINTA NDLS
News For ARO;ACO;KATE;ODP;ICPT;GPI;FENG;LINTA;NDLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
11:56 EDTODPStaples rallies after Q3 results beat estimates
Subscribe for More Information
November 18, 2014
11:40 EDTAROUrban Outfitters sinks to 52-week low after Q3 profit misses consensus
Subscribe for More Information
07:30 EDTNDLSMorgan Stanley to hold a conference
Subscribe for More Information
November 17, 2014
10:02 EDTODPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:21 EDTODPOffice Depot downgraded to Neutral from Buy at Goldman
Subscribe for More Information
November 14, 2014
15:22 EDTICPTIntercept CEO says company 'very well-positioned' in terms of balance sheet
Subscribe for More Information
07:14 EDTGPIGroup 1 Automotive board increases common stock share repurchase to $100M
07:14 EDTGPIGroup 1 Automotive increases quarterly dividend by 11.8% to 19c
Subscribe for More Information
November 13, 2014
18:40 EDTFENGOn The Fly: After Hours Movers
UP AFTER EARNINGS: TubeMogul (TUBE), up 12.4%... Weibo (WB), up 3.2%... Nordstrom (JWN), up 3.1%. ALSO HIGHER: Geron (GERN), up 30.7% after announcing a global strategic collaboration with Janssen Biotech... Baker Hughes (BHI), up 16.2% following reports that the company is in talks to be acquired by Halliburton (HAL)... Halliburton is up 1.4%... Pandora (P), up 4% after announcing a conference call to discuss Web IV proceeding... AmerisourceBergen (ABC), up 1.1% after being awarded a $4.06B government contract. DOWN AFTER EARNINGS: Retrophin (RTRX), down 6.6%... Phoenix New Media (FENG), down 8.4%... Voxeljet AG (VJET), down 8.6%... Intrexon (XON), down 1.1%... Youku Tudou (YOKU), down 5.7%... Applied Materials (AMAT), down 2.5%. ALSO LOWER: Puma Biotechnology (PBYI), down 6.9% following PB272 Phase II Trial results... EnLink Midstream (ENLK), down 4.8% after filing to sell 10.5M common units representing limited partners.
17:04 EDTFENGPhoenix New Media sees Q4 revenue RMB 439M-RMB 459M
Subscribe for More Information
17:03 EDTFENGPhoenix New Media reports Q3 adjusted EPS RMB 1.21 vs. RMB 1.06 last year
Subscribe for More Information
10:16 EDTODPOffice Depot, OfficeMax stores to open at 6pm on Thanksgiving Day
Office Depot and OfficeMax retail stores will be open from 6-9 p.m. local time on Thanksgiving Day, Nov. 27, and will re-open on Black Friday, Nov. 28, at 8 a.m.
November 12, 2014
12:00 EDTICPTKOLs say 'remains to be seen' if OCA can get accelerated approval, says Leerink
Subscribe for More Information
11:55 EDTICPTIntercept not part of talks with journals, says Deutsche Bank
Subscribe for More Information
10:34 EDTKATEOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI RPRX KATE PNK CZR KING TSLA UBNT LOCO GNRC
November 11, 2014
12:00 EDTICPTIntercept results said to be rejected by New England Journal, Bloomberg says
Subscribe for More Information
07:49 EDTAROBofA/Merrill retail and consumer analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
10:17 EDTKATEOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI ACHN RPRX ARCP SALE ZU KING UBNT KATE AWAY
08:36 EDTICPTIntercept price target lowered to $125 from $172 at FBR Capital
FBR Capital lowered its price target for Intercept shares to $125 saying its talks with experts and cardiologists indicate the company's OCA drug is unlikely to be a "silver bullet" for the treatment of nonalcoholic steatohepatitis. FBR notes that while OCA appears to improve the liver, the drug worsens many of the other derangements like lipid and glucose homeostasis. FBR decreased the probability of success in NASH to 55% from 60%, and lowered its peak OCA sales estimate to $5.2B. It keeps an Underperform rating on Intercept shares.
November 9, 2014
11:56 EDTICPTIntercept announces additional data for OCA in primary biliary cirrhosis
Intercept Pharmaceuticals announced new analyses of data from clinical trials on obeticholic acid, OCA, in patients with primary biliary cirrhosis, PBC. Six posters, including posters with new analyses of data from POISE the first Phase 3 trial in PBC in two decades are being presented at today's poster session at the American Association for the Study of Liver Disease, AASLD, Annual Meeting. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR, in development for PBC, nonalcoholic steatohepatitis, NASH, primary sclerosing cholangitis, PSC, and other chronic liver diseases.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use